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Graphical abstract
Highlights
• Serum LPS was associated with incident advanced
liver disease in the general population.
• LPS was associated with liver-related risk of hospita-
lization, cancer or death.
• The highest LPS tertile may account for up to 30% of
the risk of incident liver disease.
• The risk of liver disease was accentuated among car-
riers of the PNPLA3 I143M.
• Serum LPS was not associated with all-cause
mortality.
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Lay summary
Lipopolysaccharide, a gut-derived bacterial endotoxin,
has been implicated in the development of chronic
liver disease, but its relevance at the population level
remains unclear. We found that serum lipopolysac-
charide levels were associated with incident advanced
liver disease in the general population, with the highest
tertile accounting for up to 30% of the risk of hospitali-
zation, cancer or death related to liver disease.
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Background & Aims: Gut-derived endotoxemia has been implicated in the development of chronic liver disease, but its rele-
vance at the population level remains unclear. We analyzed whether endotoxemia is associated with incident advanced liver
disease in the general population.
Methods: Serum lipopolysaccharide (LPS) was measured in 6,727 (3,455 male and 3,272 female, mean age 53.4 ± 10.9 years,
mean bodymass index 27.2 ± 4.5) individuals participating in the Finnish population-based health examination survey FINRISK
1997. Data were linked with electronic health registers for incident advanced liver disease (hospitalization, cancer or death
related to liver disease). During a mean follow-up of 16.3 ± 3.8 years (109,282 person-years), 86 liver events occurred. Univari-
ate and multivariate Cox regression, and Kaplan-Meier analyses were performed.
Results: Serum LPS predicted incident advanced liver disease with a hazard ratio per 1 SD of 1.41 (95% CI 1.24–1.59; p <0.001)
when adjusted for age, sex, gamma-glutamyltransferase, metabolic syndrome, alcohol use, patatin-like phospholipase domain-
containing protein 3 (PNPLA3) I148M, waist-hip ratio and type 2 diabetes. This association remained robustly signiﬁcant in
additional multivariate analyses with various levels of adjustment. The association was accentuated among carriers of the
PNPLA3 risk variant. The population attributable fraction of the highest LPS tertile for liver events was 29.7%. However, LPS
was not associated with all-cause mortality.
Conclusion: Serum LPS is associated with hospitalization, cancer or death related to liver disease in the general population,
with the highest tertile potentially accounting for 30% of the risk of liver disease.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Chronic liver disease is a major health problem and an increasing
cause for morbidity and mortality.1,2 Finland has one of the high-
est liver disease mortality rates in Europe.2 The 2 most common
chronic liver diseases in Western populations are non-alcoholic
fatty liver disease (NAFLD) and alcohol-related liver disease
(ALD).3 The global prevalence of NAFLD is 25%, and with continu-
ously rising obesity rates, the incidence of NAFLD is rising too,
explaining the majority of the increasing incidence of chronic
liver disease.2,4 Alcohol-related liver disease is another major
cause of liver cirrhosis, and it is the leading cause of liver mortal-
ity in the Western world.2 Together obesity and alcohol have a
synergistic effect on the risk of liver disease.5 Genetic factors
also modify the risk of liver disease. The 2 most important identi-
fied genetic risk variants are patatin-like phospholipase domain-
containing 3 (PNPLA3) at rs738409 C>G and transmembrane 6Key words: Cirrhosis; Endotoxemia; Genetics; Gut; Hospitalization.
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E-mail address: ville.mannisto@kuh.fi (V. Männistö).superfamily member 2 (TM6SF2) at rs58542926 C>T. In Western
populations, 35–40% of individuals are heterozygous and 5%
homozygous for the PNPLA3 variant,6 whereas about 7% are het-
erozygous for TM6SF2.7
The role of gut microbiota in the pathogenesis of various liver
diseases has garnered interest in recent years. Alterations in gut
microbiota have been associatedwith liver cirrhosis, ALD (including
alcoholic hepatitis) and NAFLD. Interestingly, the degree of gut
microbiota dysbiosis associates with the stage of liver injury.8,9
However, the pathogenetic mechanisms behind these associations
are still largely unknown. The relevance of gut dysbiosis for devel-
opment of liver disease on a population level is also unknown.
Lipopolysaccharide (LPS) is a bacterial endotoxin, derived from
intestinal gram-negative bacteria. In healthy individuals, only small
amounts of LPS translocate through the gut and reach the liver,
where LPS is taken up by Kupffer cells and removed.10 This is an
important process with the aim of preventing activation of toll-like
receptor 4 (TLR4), which would lead to the release of inflammatory
cytokines, induction of liver fibrosis development, and progression
to cirrhosis.11 As a marker of gut dysbiosis and increased intestinal
translocation, increased serum LPS activity has been associated
with ALD, NAFLD and non-alcoholic steatohepatitis (NASH), and
with liver fibrosis and hepatocellular carcinoma (HCC).11,12
Research ArticleWe aimed to investigate if the level of circulating LPS predicts
liver-related outcomes at the population level in a cohort of 6,272
individuals from the general population.
Materials and methods
Study population
The National FINRISK 1997 Study is a population-based health sur-
vey that originally consisted of 8,446 individuals (from 11,500
invited). It was conducted in 5 geographical areas in Finland, and
the age range of study participantswas 25 to 74 years.13 The survey
methods follow theWHOMONICAprotocol.14 The study included a
self-administered questionnaire and clinical examination of
weight, height, and blood pressure measurements, as well as
blood samples. The study was approved by the ethics committee
of the National Public Health Institute, and it was conducted
according to the Declaration of Helsinki. All individuals gave
informed consent for the study and for future registry linkage.
Baseline variables
Of the original sample of 8,446 adults, 6,727 individuals who had
an available serum LPSmeasurement were included in this study.
At baseline, study participants were asked to report how often
they consumed alcoholic beverages during the previous year
and the average amount they consumed per week during the
previous month. Average alcohol consumption (grams of 100%
alcohol per day) was calculated based on these data. The respon-
dents were also questioned how often they drank alcohol to the
level that they felt intoxicated (weekly, monthly or less often).
In addition, smoking status (never, former, current smoker),
amount of smoking (number of cigarettes per day) and exercise
habits (frequency of moderate-intensity or high-intensity physi-
cal exercise for at least half an hour) were asked. Diabetes was
defined either by taking diabetes medication or a known diabetes
diagnosis. Metabolic syndromewas defined according to the Joint
Interim Statement criteria.15
Laboratory analysis
Participants were asked to fast 4 h and to avoid heavier meals
prior to blood sampling. The median fasting time was 5 (inter-
quartile range 3–7) h. Lipids and gamma-glutamyltransferase
(GGT) measurements were done from fresh serum samples. The
rest of the serum and plasma biomarkers were determined
from samples stored at -70°C. Ultrasensitive C-reactive protein
(CRP) was determined with Architect c8000 analyzer (Abbott
Laboratories, Abbott Park, IL). Serum endotoxin activities were
determined by a Limulus amebocyte lysate assay coupled with a
chromogenic substrate (HyCult Biotechnology B.V., Uden, the
Netherlands), and the interassay coefficient of variation was
9.2% (n = 75). The laboratory analyses have been described in
detail previously.16 Non-high-density lipoprotein (HDL) choles-
terol was calculated by subtracting HDL from total cholesterol.
PNPLA3 at rs738409, TM6SF2 at rs58542926, membrane-bound
O-acyltransferase domain-containing protein 7 (MBOAT7) at
rs641738 and hydroxysteroid 17-beta dehydrogenase (HSD17B13)
at rs72613567were genotyped using Illumina’s 610K,Omniexpress
and HumanCoreExpress chips.
Sources of outcome data
Follow-up data for hospitalizations were obtained from the
National Hospital Discharge Register, which covers all hospitali-
zations in Finland beginning in 1969. Data for cancers wereJHEP Reports 2019obtained from the Finnish Cancer Registry, and vital status and
cause of death data were obtained from Statistics Finland,
which systematically collects data about the deaths of all Finnish
citizens. In Finland, each person who dies is by law assigned a
cause of death (in accordancewith the International Classification
of Diseases) to the official death certificate, issued by the treating
physician based on medical or autopsy evidence, or forensic evi-
dence when necessary; the death codes are then verified bymed-
ical experts at the register and recorded according to systematic
coding principles. One or several International Statistical Classifi-
cation of Diseases and Related Health Problems (ICD) diagnoses
are assigned to each hospitalization at discharge; these diagnosis
codes are systematically recorded in the National Hospital Dis-
charge Register. Data collection to all these registries is obligatory
and general quality is consistent and complete. Linkage was per-
formed using the unique personal identifiers assigned to all Fin-
nish residents. Follow-up for death and hospitalizations was
until December 2013, and for cancers until December 2012.
Deﬁnition of outcome events
The primary study endpoint was the first hospitalization due to
advanced liver disease or liver-related death or a diagnosis of pri-
mary liver cancer, whichever came first. Regarding liver death,
outcome events comprised ICD8/9 codes 155.0, 570-573 and
155.0, and ICD10 codes K70-K77 and C22.0, in line with previous
studies.17,18 Regarding hospitalization, we included events with
the following ICD codes reflective of advanced liver disease, cir-
rhosis or equivalent: ICD8: 571.0, 571.8, 571.9, 573.0, 573.9;
ICD-9: 571.1, 571.2, 571.3, 571.5, 571.8 and ICD10: K70.1-K70.4,
K70.9, K72.0, K72.1, K72.9, K74.0-K74.2, K74.6. Liver cancer was
defined by ICD8/9 code 155.0 and ICD10 code C22.0.We excluded
participants with records showing that any liver event had
occurred before the study baseline.
Statistics
For comparing groups, we used Chi-squared, Mann-Whitney U,
or Kruskal-Wallis tests as appropriate. Correlations between con-
tinuous variables were calculated by Spearman correlation. The
effect of LPS on the risk of liver events was analyzed by univariate
and multivariate Cox regression with time to first liver event as
the outcome variable. LPS was tested both as a continuous vari-
able and divided into tertiles. In the multivariate Cox regression
analysis, we adjusted for variables associated with liver events
with a p value <0.1 and/or variables with known association
with liver disease from previous studies. To prevent overfitting
from the inclusion of too many variables, we performed multiple
multivariate models with various levels of adjustment. The main
multivariate model was adjusted for well-acknowledged risk fac-
tors of liver disease, also taking into account the number of liver
events to prevent overfitting: age, sex, waist-hip ratio, diabetes,
average alcohol use, metabolic syndrome, GGT, and PNPLA3
I148M variant. Additional models were adjusted for age and
sex, significant (p <0.1 on univariate analysis) metabolic factors,
alcohol factors, other lifestyle factors, genetics, GGT and CRP.
Two-way interaction effects for incident liver events were
tested between LPS and PNPLA3, TM6SF2 and MBOAT7 risk var-
iants by including LPS and the genetic risk factors as well as an
interaction term in the Cox regression. In case of a significant
interaction effect, we performed subgroup analyses to evaluate
how the risk estimate of LPS differed in the subgroups.
The population attributable fraction for the highest LPS tertile
was calculated, following Miettinen,19 as pc(1−1/HR), where pc isvol. 1 | 345–352 346
the prevalence of the highest LPS tertile among individuals who
developed the liver outcome and HR is the hazard ratio for liver
outcomes in the highest LPS tertile. We used the Kaplan-Meier
method and Log-Rank test to analyze the cumulative incidence
of liver events and all-cause mortality by LPS tertiles. p <0.05
was considered statistically significant. A possible non-linear
relationship between LPS and the liver outcome was examined
using the penalized spline smoothing method.
Data were analyzed with SPSS version 25 (IBM Inc., Armonk,
NY and R software version 3.6.0).
Results
Clinical characteristics
The study cohort consisted of 6,727 individuals, 3,455 men and
3,272 women, mean age 53.4 ± 10.9 and mean body mass index
(BMI) 27.2 ± 4.5 (Table 1). Mean follow-up was 16.3 ± 3.8 years
(range 0–17.8, 109,282 person-years of follow-up). During
follow-up, 86 individuals experienced a severe liver event (first
hospitalization due to advanced liver disease or liver disease-
related death or a diagnosis of primary liver cancer). The first liver
event occurred a mean of 10.6 ± 3.7 years (range 1–18 years) after
baseline. Of the liver events, 57 (66%) occurred among men and
29 (34%) among women, with a mean time to first event of 10.4
and 11.0 years, respectively (p <0.001). The first recorded liver
event was hospitalization in 31 cases, liver cancer in 18 cases, and
liver disease-related death in 37 cases.
The mean LPS activity in serum was 63.0 ± 37.4 pg/ml. We
divided the study cohort into tertiles based on the LPS level,
those with LPS <43.4 pg/ml (n = 2,258, mean 31.6 ± 33 pg/ml),
those with 43.4–68 pg/ml (n = 2,228, mean 54.7 ± 54.3 pg/ml)
and those with >68 pg/ml (n = 2,241, mean 102.8 ± 91.1 pg/ml).
There were statistically significant differences among the LPS
tertiles in all baseline variables except sex, alcohol use (grams
per week and status of alcohol use), frequency of intoxication epi-
sodes, amount of exercise, TM6SF2 rs58542926 genotype and
MBOAT7 rs641738 genotype (Table 1). We found a trend towards
a higher burden ofmetabolic risk factors in the higher LPS tertiles,
but less smoking and non-significant differences in alcohol expo-
sure (Table 1). Individuals in the highest LPS tertile were slightly
less often PNPLA3 I148M carriers than those in the lowest or mid-
dle tertiles (38% vs. 41%, p = 0.03).
The correlation coefficient between LPS and BMI was 0.232,
(p <0.001). There was no meaningful correlation between LPS
and weekly alcohol intake (r = -0.004, p = 0.776), carbohydrate-
deficient transferrin (r = -0.098, p <0.001), GGT (r = 0.186,
p <0.001) or waist-hip ratio (r = 0.187, p <0.001).
As thrombocytopenia might reflect underlying asymptomatic/
undetected advanced liver disease, we analyzed whether there
was a correlation between platelet level and LPS in a subgroup
of 536 individuals with platelet measurements available. How-
ever, we found no such correlation between LPS and platelet
level (r = -0.004, p = 0.92, Fig. S1). In addition, we tested the cor-
relation between LPS and CRP, but found only a weak correlation
(r = 0.15, p <0.001, Fig. S2).
Serum LPS predicts liver-related outcome
Univariate Cox regression results are shown in Table S1. Serum
LPS level at baseline predicted liver-related outcomes on univari-
ate analysis (HR per 1 SD 1.41; 95% CI 1.24–1.59; p <0.001). In
the main multivariate model shown in Table 2, the HR for LPS
in predicting incident advanced liver disease was 1.31 (95% CIJHEP Reports 20191.11–1.54; p <0.001). The HR for LPS remained fairly stable
(1.3–1.5) in additional models with various level of adjustment
(Table 2).
When adjusted for age and sex, individuals in the highest LPS
tertile had a 2-fold increased risk of incident severe liver disease
compared to those in the lowest tertile (Fig. 1).
PNPLA3 I143M modiﬁes the association between LPS and
liver-related outcomes
We found a significant interaction effect for liver events between
LPS and PNPLA3 I143M (p = 0.015 for the interaction term), but
not with the other genetic risk variants. When we stratified the
cohort by PNPLA3 I143M carrier status (heterozygote/homozy-
gote vs. no risk variant), we found that HRs for liver events of
the highest LPS tertile were higher among individuals with the
G variant of PNPLA3 (HR 3.7; 95% CI 1.604–8.646; p = 0.002)
than among those without the PNPLA3 risk variant (HR 2.6; 95%
CI 1.103–6.250; p = 0.029) (Fig. 2).
Population attributable fraction
The population attributable fraction of the highest LPS tertile for
incident advanced liver disease was 26.8% when adjusting for
age and sex, and 29.7% when additionally adjusting for metabolic
syndrome, diabetes, waist-hip ratio, weekly alcohol use, GGT and
PNPLA3 I143M variant.
Serum LPS had no association with all-cause mortality
During follow-up, 1,417 individuals died. We found no difference
in all-cause mortality according to the LPS tertile (Fig. 3); com-
pared to the lowest LPS tertile, HR for the middle tertile was
1.04 (95% CI 0.91–1.18; p = 0.58) and HR for the highest tertile
was 1.08 (95% CI 0.95–1.23; p = 0.22). This indicates that the com-
peting risk of death does not explain the association between LPS
and liver events.
Discussion
Our main finding was that serum LPS is independently associated
with incident advanced liver disease in the general population.
This association remained significant after adjusting for relevant
confounders in multiple multivariate models. As circulating LPS
(endotoxemia) is likely derived from the gut, our findings suggest
that the gut is an important player in the development of liver
disease on a population level. In fact, we estimated that up to
27–30% of cases of advanced liver disease in the population are
attributable to a high LPS level (highest tertile). Therefore, target-
ing the factors that lead to increased mucosal permeability and
endotoxemia may be a key in preventing advanced liver disease.
To our knowledge, this is the first study linking serum LPS with
incident advanced liver disease at a population level.
An increase in serum LPS levels likely reflects endotoxemia
resulting from increased mucosal permeability, impaired intest-
inal mucosal integrity and alterations in gut microbiota, because
gram-negative bacteria are known to produce LPS.10 Alterations
in gut microbiota are linked with many types of chronic liver dis-
ease including NAFLD, ALD, viral hepatitis, liver cirrhosis and
HCC.8 These changes, together with altered intestinal capacity
to neutralize LPS toxicity, decreased liver degradation of LPS,
and disrupted mucosal integrity, predispose to endotoxemia
and progression of liver disease.8,20
Previous clinical studies reporting associations between endo-
toxemia and advanced liver diseases have been performed invol. 1 | 345–352 347
Table 1. Baseline characteristics of the whole study population.
All subjects
(mean ± SD)
LPS lowest tertile
(mean ± SD)
LPS middle tertile
(mean ± SD)
LPS highest tertile
(mean ± SD)
p value
n = 6,272 n = 2,258 n = 2,228 n = 2,241
Sex male/female (%) 3,455/3,272 (49) 1,123/1,125 (50) 1,162/1,066 (48) 1,170/1,071 (48) 0.165
Age (years) 53.4 ± 10.9 52.5 ± 11.3 53.5 ± 10.9 54.1 ± 10.3 <0.001
BMI (kg/m2) 27.2 ± 4.5 26.1 ± 4.3 27.2 ± 4.3 28.3 ± 4.6 <0.001
Waist circumference (cm) 90.3 ± 13.4 87.1 ± 12.9 90.1 ± 13.1 93.6 ± 13.4 <0.001
Waist-hip ratio 0.88 ± 0.1 0.86 ± 0.1 0.88 ± 0.1 0.90 ± 0.1 <0.001
Metabolic syndrome (%) 1,355 (20) 283 (13) 406 (18) 666 (30) <0.001
Type 2 diabetes (%) 478 (7) 111 (5) 170 (8) 197 (9) <0.001
Alcohol use (g/week) 72 ± 139 69 ± 130 71 ± 129 77 ± 156 0.760
Alcohol use 0.488
Life-time abstainer 600 (9) 185 (8) 203 (9) 212 (10)
Current abstainer 349 (5) 120 (5) 108 (5) 121 (6)
Alcohol user 5,680 (84) 1,927 (86) 1,886 (86) 1,867 (85)
Frequency of intoxication episodes 0.567
Less often 4,219 (63) 1,440 (77) 1,407 (77) 1,372 (75)
Monthly 944 (14) 305 (16) 313 (17) 326 (18)
Weekly or more often 374 (6) 124 (7) 117 (6) 133 (7)
Systolic blood pressure (mmHg) 139.0 ± 20.4 136.4 ± 20.2 139.2 ± 20.7 141.4 ± 20.1 <0.001
Diastolic blood pressure (mmHg) 84.0 ± 10.9 82.3 ± 10.8 83.9 ± 10.7 85.8 ± 11.0 <0.001
Total cholesterol (mmol/L) 5.7 ± 1.0 5.4 ± 1.0 5.7 ± 1.0 6.0 ± 1.1 <0.001
HDL cholesterol (mmol/L) 1.4 ± 0.4 1.4 ± 0.3 1.4 ± 0.4 1.3 ± 0.4 <0.001
Non-HDL cholesterol (mmol/L) 4.2 ± 1.0 3.9 ± 0.9 4.3 ± 0.9 4.7 ± 1.0 <0.001
GGT (U/L) 38.0 ± 62.5 32.6 ± 36.0 35.1 ± 37.1 46.4 ± 94.6 <0.001
CDT (%) 0.61 ± 0.26 0.64 ± 0.27 0.60 ± 0.24 0.59 ± 0.26 <0.001
CRP (mg/L) 2.5 ± 5.8 2.5 ± 7.0 2.3 ± 4.6 4.7 ± 1.1 <0.001
Smoking 0.003
Current 1,459 (22) 534 (25) 459 (21) 466 (21)
Former 1,642 (24) 505 (23) 539 (25) 598 (27)
Never 3,416 (51) 1,144 (52) 1,157 (54) 1,115 (51)
Exercise 20-30 mins per week 0.277
At least 2 times a week 3,784 (56) 1,296 (58) 1,252 (58) 1,236 (57)
2-4 times a month 1,740 (26) 597 (27) 552 (26) 591 (27)
Less often 1,042 (16) 325 (15) 361 (17) 356 (16)
PNPLA3 rs738409 0.033
CC 3,520 (52) 1,176 (59) 1,153 (60) 1,191 (61)
CG 2,042 (30) 721 (36) 655 (34) 666 (34)
GG 320 (5) 103 (5) 128 (7) 89 (4)
TM6SF2 rs58542926 0.129
CC 5,218 (78) 1,750 (87) 1,725 (89) 1,743 (89)
CT 664 (10) 249 (12) 214 (11) 201 (10)
TT 19 (0.3) 8 (0.4) 3 (0.2) 8 (0.4)
MBOAT7 rs641738 0.873
CC 1,962 (29) 670 (39) 655 (39) 637 (38)
CT 2,345 (35) 781 (45) 774 (46) 790 (47)
TT 780 (11) 269 (16) 249 (15) 262 (16)
HSD17B13 rs72613567 0.941
T/T 3,657 (62) 1,253 (63) 1,196 (62) 1,208 (62)
T/TA 1,968 (33) 656 (33) 655 (34) 657 (34)
TA/TA 265 (5) 94 (4) 86 (4) 85 (4)
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Table 2. Hazard ratios for incident severe liver events (hospitalization, liver
cancer or liver deaths) according to serumLPS based on Cox regression analyses.
Adjusted HR (/1 SD) of LPS 95% CI p value
Main model 1.31 1.11-1.54 0.001
Sensitivity analyses
Model 1 1.41 1.24-1.61 <0.001
Model 2 1.35 1.15-1.58 <0.001
Model 3 1.37 1.16-1.62 <0.001
Model 4 1.40 1.20-1.64 <0.001
Model 5 1.49 1.30-1.71 <0.001
Model 6 1.39 1.19-1.63 <0.001
Model 7 1.29 1.10-1.51 0.001
BMI, body mass index; GGT, gamma-glutamyltransferase; HDL, high-density lipopro-
tein; HR, hazard ratio; HSD17B13, hydroxysteroid 17-beta dehydrogenase 13; LPS,
lipopolysaccharide; MBOAT7, membrane-bound O-acyltransferase domain-containing
protein 7; PNPLA3, patatin-like phospholipase domain-containing protein 3; TM6SF2,
transmembrane 6 superfamily member 2.
Adjusted for: Main model: Age, sex, GGT, metabolic syndrome, alcohol usage, PNPLA3
at rs738409, waist-hip ratio and type 2 diabetes. Model 1: Age and sex. Model 2: Age,
sex, BMI, waist-hip ratio, elevated blood pressure, cholesterol, non-HDL cholesterol.
Model 3: Age, sex and alcohol (alcohol usage, intoxication episodes). Model 4: Age,
sex and alcohol (carbohydrate-deficient transferrin and intoxication episodes).
Model 5: Age, sex, genetics (PNPLA3 rs738409, TM6SF2 rs58542926, MBOAT7
rs641738, HSD17B13 rs72613567). Model 6: Age, sex and lifestyle factors (smoking,
alcohol use, amount of exercise, intoxication episodes). Model 7: GGT and C-reactive
protein.quite small populations. For example, endotoxemia was asso-
ciated with NAFLD in a general population cohort of 920 indivi-
duals, but not with liver fibrosis measured by elastography.21
However, in a smaller study of 237 individuals by the same
authors, endotoxemia was associated with NASH and liver fibro-
sis.22 Endotoxemia has also been linked with ALD.8 Interestingly,
it seems that the effect of alcohol on intestinal permeability is
transient in the absence of pre-existing liver cirrhosis.23 How-
ever, that indicates that also binge drinking, even without liver
disease, can lead to increased LPS activity and possibly activation
of TLR4 in the liver.24 Epidemiological data strongly suggest that
binge drinking is responsible for an increased incidence of cirrho-
sis.25There is also evidence linking endotoxemia with other
chronic liver diseases including viral hepatitis, primary biliary
cholangitis and primary sclerosing cholangitis.11 Interestingly,
endotoxemia has been linked with the development of portal
hypertension in mice,26 and also with complications from portal
hypertension in those with liver cirrhosis. For example, higher
levels of endotoxemia have been reported in those with liver cir-
rhosis and hepatic encephalopathy27 and it has been hypothe-
sized to be a trigger of coagulopathy in cirrhosis.28 These
findings support our results of serum LPS as a predictor or indica-
tor of advanced liver disease.
It is important to keep in mind that although LPS can acti-
vate inflammatory pathways and induce progression of
NAFLD29 and ALD,30 there may also be other gut-derived meta-
bolites (for example bile acids), which are important in the
pathogenesis of liver diseases.29 Taken together, our studyBMI, body mass index; CDT, carbohydrate-deﬁcient transferrin; CRP, C-reactive protein; G
17-beta dehydrogenase 13; LPS, lipopolysaccharide; MBOAT7, membrane-bound O-acylt
containing protein 3; TM6SF2, transmembrane 6 superfamily member 2. Missing individua
episodes n = 1,190, exercise n = 161, PNPLA3 rs738409 n = 845, TM6SF2 rs58542926 n = 82
LPS tertiles was tested with Kruskal-Wallis test and Pearson Chi-Square test (between ca
JHEP Reports 2019suggests that gut microbiota-derived endotoxemia (as a marker of
LPS in the circulation) is associated with advanced liver disease,
highlighting the importance of the gut-liver axis. Thus, more
research is needed on the role of gutmicrobiota in different liver dis-
eases, and to identify gut microbiota-derived molecules that could
act as novel biomarkers.
Our study raises the question of whether LPS could be used
as a biomarker for predicting advanced liver disease. We
found a rather small but significant association of LPS with
liver-related outcomes (Fig. 1, Table 2). However, when we
analyzed study individuals in LPS tertiles, those in the highest
LPS tertile had a higher cumulative risk of liver-related out-
comes compared to others (Fig. 1). Whether LPS measurements
could be used as an independent marker (or as part of a non-
invasive score) of advanced liver disease, for example in a
selected population with known liver disease, should be tested
in future studies.
We found that those in highest LPS tertile had significantly
higher cumulative incidence for liver events, but there was no
difference in all-cause mortality (Fig. 3). This suggests that the
association between LPS and liver events are not confounded
by competing risk issues. Previously, serum LPS activity has
been associated with metabolic syndrome and it has been sug-
gested that LPS-mediated processes could be key factors in
metabolic disturbances associated with obesity.31 However,
also in that case, circulating LPS could originate from the gut
and reflect underlying NAFLD, which is a cause of many meta-
bolic disturbances.32 This is supported by the fact that in our
cohort LPS was an independent predictor of liver-related out-
comes after adjusting for metabolic factors. We acknowledge
that not all LPS in the circulation is derived from the gut, as it
can also originate from the oral cavity, respiratory, and geni-
tourinary tracts, or from food; it can also be modulated by anti-
biotics.33 However, the gut is the major reservoir of LPS,
because the gut microbiota is the largest source of gram-
negative bacteria in the body.34
To our knowledge, this is the first population study to analyze
interactions between LPS and liver disease-associated genetic
variants. Interestingly, circulating LPS was a stronger risk factor
for liver-related outcomes in those with PNPLA3 I148M G risk
allele compared to those without the risk allele (Fig. 2). However,
this finding should be interpreted with caution, because the con-
fidence intervals were very wide, which implies that statistical
power is suboptimal for this subgroup analysis. It is known that
PNPLA3 I148M variant as such causes more aggressive liver dis-
ease and it is suggested to contribute directly to fibrogenesis
and carcinogenesis via retinol availability in stellate cells.35 The
explanation of our results is possibly that PNPLA3 I148M could
be a surrogate marker of NAFLD, because those with risk var-
iants have markedly higher liver fat content.36 Alternatively,
variants could confer an additive risk of liver disease and at
this point it is unclear whether the PNPLA3 genotype could
have a direct effect on gut microbiota (the expression level of
PNPLA3 in the gut is minimal37), thus increasing the probability
of liver disease.GT, g-glutamyltransferase; HDL, high-density lipoprotein; HSD17B13, hydroxysteroid
ransferase domain-containing protein 7; PNPLA3, patatin-like phospholipase domain-
ls in different categories: Smoking n = 210, alcohol use n = 98, frequency of intoxication
6,MBOAT7 rs641738 n = 1,640, HSD17B13 rs72613567, n = 837. The difference between
tegorial variables).
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Fig. 1. Cumulative incidence by Kaplan-Meier analysis and age- and sex-adjusted hazards ratios by Cox regression analysis of LPS tertiles for incident
advanced liver disease. LPS, lipopolysaccharide.
Research ArticleA strength of this study is the large and well-characterized
population-based cohort of men and women. Another
strength is the longitudinal, complete follow-up and use of
hard endpoints (hospital admission, cancer, death) derived
from reliable and mandatory national registries. Furthermore,
we were able to adjust our analyses for multiple known con-
founders. We also excluded the cases with chronic viral hepa-
titis at baseline or during follow-up to avoid confounding by
these factors.
Our population-based study has some limitations. First, because
of the study design, we cannot conclude with certainty that LPS is a8
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Fig. 2. Hazard ratios for incident liver disease stratified by the PNPLA3 I143M
carrier status (heterozygote/homozygote vs. no risk variant). Mean ± SD of
LPS level is shown according to groups. LPS, lipopolysaccharide; PNPLA3,
patatin-like phospholipase domain-containing protein 3.
JHEP Reports 2019causative player in liver disease. Secondly, alcohol consumption
was measured only once at baseline, but we have previously
reported that, in general, 82% of individuals in the FINRISK and
Health 2000 surveys show stable alcohol consumption over time.38
Furthermore,we did not have liver biopsy or other directmeasures
of the possible presence of liver disease at baseline. However, we
did have GGT measurements, and GGT is the most sensitive liver
enzyme for liver injury and disease.39 Importantly, we also
excluded individuals with known clinical liver disease at baseline.
Low platelet levels are a common finding in advanced liver dis-
ease,40 and could be an additional marker of underlying liverYears
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Fig. 3. Cumulative incidence by Kaplan-Meier analysis for overall survival by
LPS tertile. LPS, lipopolysaccharide.
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disease at baseline in this cohort. However,we found no correlation
between LPS level and platelet count. All of this supports that an
association between gut endotoxemia and the risk for liver disease
exists beyond that explained by possible undetected underlying
advanced liver disease.JHEP Reports 2019Conclusion
Serum LPS is associated with incident advanced liver dis-
ease in the general population. We found that up to 30% of
such liver disease may be attributed to high circulating LPS
levels.Abbreviations
ALD, alcoholic liver disease; BMI, body mass index; CRP, C-reactive
protein; GGT, gamma-glutamyltransferase; HDL, high-density lipo-
protein; HR, hazard ratio; HSD17B13, Hydroxysteroid 17-beta dehy-
drogenase 13; LPS, lipopolysaccharide; MBOAT7, membrane-bound
O-acyltransferase domain-containing protein 7; NAFLD, non-
alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis;
PNPLA3, patatin-like phospholipase domain-containing protein 3;
TLR4, toll-like receptor 4; TM6SF2, transmembrane 6 superfamily
member 2.
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